EcoDrugPlus

Dihydropyrimidine Dehydrogenase B

Ensembl ID : ENSACLG00000001822
Gene Symbol: DPYDB
1 Cross references
217 Possible Orthologues:

Discoidin Domain Receptor Tyrosine Kinase 2

Ensembl ID : ENSACLG00000005714
Gene Symbol: DDR2
1 Cross references
205 Possible Orthologues:

Discoidin Domain Receptor Tyrosine Kinase 2

Ensembl ID : ENSACLG00000012375
Gene Symbol: DDR2
1 Cross references
189 Possible Orthologues:

Dopamine Receptor D1

Ensembl ID : ENSACLG00000002123
Gene Symbol: DRD1
3 Cross references
188 Possible Orthologues:

Dopamine Receptor D1b

Ensembl ID : ENSACLG00000010438
Gene Symbol: DRD1B
1 Cross references
200 Possible Orthologues:

Dopamine Receptor D2

Ensembl ID : ENSACLG00000019121
Gene Symbol: DRD2
3 Cross references
207 Possible Orthologues:

Dopamine Receptor D3

Ensembl ID : ENSACLG00000026861
Gene Symbol: DRD3
3 Cross references
203 Possible Orthologues:

Dopamine Receptor D4

Ensembl ID : ENSACLG00000013283
Gene Symbol: DRD4
3 Cross references
174 Possible Orthologues:

Dopamine Receptor D5

Ensembl ID : ENSACLG00000013106
Gene Symbol: DRD5
2 Cross references
164 Possible Orthologues:

Dual Specificity Mitogen-Activated Protein Kinase Kinase 2

Ensembl ID : ENSACLG00000023158
Gene Symbol: LOC113016221
3 Cross references
218 Possible Orthologues:

Dual Specificity Mitogen-Activated Protein Kinase Kinase 2-Like

Ensembl ID : ENSACLG00000002553
Gene Symbol: LOC113011047
3 Cross references
202 Possible Orthologues:

Ectonucleotide Pyrophosphatase/phosphodiesterase 2

Ensembl ID : ENSACLG00000012318
Gene Symbol: ENPP2
3 Cross references
226 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).